Thursday, 26 April 2018

Parkinson’s Disease Drugs for Treating Motor Fluctuations & Dyskinesia

Parkinson’s disease (PD) drugs play an important role to treat disorders disturbing motor neuron activities including depression, dementia, tremor, and rigidity. The risk of the disease may increase with age and it mostly affects individual over fifty years of age.

To get more details at :

Development of Drugs to Treat CNS Disorders to Boost Demand

Several therapies used to treat PD include dopamine agonist therapy, levodopa therapy, COMT inhibitor therapy, MAO-B inhibitor therapy, and others.

The levodopa therapy segment is expected to account for the largest share till 2022. It is widely adopted as it is considered as the strong treatment for PD. The benefits of the therapy can be observed quickly after administration. For instance, Adamas Pharmaceuticals’ amantadine extended-release capsules called Gocovri has received approval from the U.S. Food and Drug Administration (FDA) in 2017. The drug can be used to treat dyskinesia among patients who are currently undergoing levodopa-based therapy, with or without associated dopaminergic drugs.

The dopamine agonist therapy segment is likely to show strong growth from 2017 to 2022 as the therapy is effective in treating central nervous system (CNS) disorders caused due to hypodopaminergic conditions. It applies its anti-parkinsonian ability by stimulating the postsynaptic dopamine receptors and can improve motor functions at initial stage of PD. High usage of dopamine drug among the general physicians is growing due to therapeutic benefits witnessed during treatment of dyskinesia and motor fluctuations.  

Market Overview

According to a report made available by Radiant Insights, Inc.; the global Parkinson’s diseases (PD) drugs market is anticipated to display substantial growth by 2022. Rise in elderly population, high occurrence of neurogenerative diseases, research and development efforts, and pipeline of numerous drugs can impel the market over the projected period (2017 to 2022). Additionally, growing awareness regarding the disease and growing expenses for research and development (R&D) can boost market growth. Patent expiration of many drugs and high cost of treatment can restrain the market growth.

Key companies operating in the market include Acadia Pharmaceuticals Inc.; Valeant Pharmaceuticals International, Inc.; Abbvie Inc.; Impax Laboratories, Inc.; and Merck & Co., Inc.

Download free request sample at :

No comments:

Post a Comment